Jiangsu Egens Biotechnology has in-licensed China rights to a hepatitis C diagnostic test from BATM, an Israeli networking technology company with a diagnostic subsidiary, Adaltis. In 2014, Egens and Adaltis set up a China JV to import diagnostic products. The CFDA approved Adaltis’ hepatitis C diagnostic in 2015, and the JV has contracted with Sinopharm to distribute the device in China. Egens says it combines biological material development, diagnostic reagent manufacturing and trade.
